Holen Sie sich die Stockscreener-App
11.70
0.34%
0.04
Schlusskurs vom Vortag:
$11.66
Offen:
$11.27
24-Stunden-Volumen:
32,573
Relative Volume:
0.36
Marktkapitalisierung:
$253.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+14.59%
1M Leistung:
-9.02%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.76
$12.13
1-Wochen-Bereich:
$10.23
$12.13
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
11.70 | 221.44M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet - MSN
Aardvark Therapeutics (NASDAQ:AARD) Rating Lowered to Sell at Wall Street Zen - Defense World
Aardvark Therapeutics reshuffles leadership amid Phase 3 study - Investing.com Australia
Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO - TipRanks
Aardvark Therapeutics reshuffles leadership amid Phase 3 study By Investing.com - Investing.com UK
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - The Manila Times
Equities Analysts Set Expectations for AARD FY2025 Earnings - Defense World
Royal Bank of Canada Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $20.00 - Defense World
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May - The Manila Times
Aardvark Therapeutics, Inc. to Present at Key Healthcare Conferences in May 2025 - Nasdaq
Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com
Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com
Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com
BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):